MMP19 and hydrops fetalis: Relative to finerenone, canagliflozin (OR = 1.53, 95% CI 1.25-1.88) and RASi (OR = 1.31, 95% CI 1.10-1.57) were associated with higher risk of adverse events.<h4>Conclusion</h4>Compared with placebo, finerenone was associated with lower risk of CV death and worsening HF events.